Table 1

Cases of new-onset uveitis associated with infliximab

Patient 1Patient 2Patient 3Patient 4
Age (sex)84 (F)50 (F)14 (F)17 (M)
DiseaseRARAJIACrohn’s disease
Ocular involvementScleritisScleritisChronic iridocyclitisNone
Duration of systemic disease10 yearsUnknownUnknown2 years
New-onset uveitisMEDense vitritisMERetinal vasculitis
Duration of infliximab treatment before onset of ocular PAEs4 months5 months10 months2 years
Modification of anti-TNFSwitch to TCZStopSwitch to ADAContinued, then switch to ADA
  • ADA, adalimumab;F, female;JIA, juvenile idiopathic arthritis;M, male;ME, macular oedema;PAE, paradoxical adverse effect;RA, rheumatoid arthritis;TCZ, tocilizumab;TNF, tumour necrosis factor.